In a report released on August 11, Marc Goodman from SVB Securities maintained a Buy rating on Marinus (MRNS – Research Report), with a price target of $27.00. The company’s shares closed yesterday at $5.68.
According to TipRanks, Goodman is a 3-star analyst with an average return of 2.5% and a 48.45% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Jazz Pharmaceuticals, and Neurocrine.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $24.50 average price target, representing a 331.34% upside. In a report released on August 12, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $17.00 price target.
The company has a one-year high of $13.15 and a one-year low of $3.97. Currently, Marinus has an average volume of 335.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
Read More on MRNS:
- Fulcrum Therapeutics (FULC) Gets a Buy from SVB Securities
- Viridian Therapeutics (VRDN) Receives a Buy from SVB Securities
- SVB Securities Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)
- SVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
- SVB Securities Sticks to Its Buy Rating for Kinnate Biopharma (KNTE)